Objectives: We evaluated the risk of fracture associated with hypotension-related adverse drug reaction caused by taking alpha blockers to treat benign prostatic hyperplasia (BPH).
Methods: We used the Health Insurance Review and Assessment Service database from January 1st 2005 to June 30th 2006 for this study. The male patients with BPH and who had a prescription for alpha blockers following any fractures were defined as the cases. We set the 20 day long hazard period prior to the index date and the four control periods whose lengths were same with hazard period. After 1:4 matching of the hazard and control periods, conditional logistic regression was used to calculate the odds ratios for the risk of fractures as related to the alpha blocker exposure.
Results: Doxazosin and tamsulosin showed the increased risk of fractures, whereas terazosin did not. After stratification using the defined daily doses, a protective effect was shown for the patients who took terazosin at the doses lower than 0.4 DDD and the hazardous effect at the doses higher than or equal to 0.4 DDD. There was no significant difference for the risk of patients taking tamsulosin at the doses higher than 1.0 DDD but there was a statistically significant increase in the risk at the doses higher than or equal to 1.0 DDD.
Conclusions: Alpha blockers for BPH may increase the risk of fracture in elderly patients who have comorbidities and take the concomitant medications. Alpha blockers need to be prescribed with caution, although some have high prostate specificity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3961/jpmph.2009.42.3.165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
α-Blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
Int J Urol
January 2025
Department of Urology, Hokushin General Hospital, Nakano, Japan.
TEMPOUR: A Randomized Controlled Trial Assessing Perioperative Use of An Alpha-1-Blocker to Reduce Postoperative Urinary Retention Following Transanal Endoscopic Microsurgery Procedures.
Dis Colon Rectum
January 2025
Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, Canada.
Background: Transanal endoscopic microsurgery is a treatment option for a wide range of rectal lesions. Postoperative urinary retention is a frequently associated complication. Some studies have suggested that the use of alpha-1-blockers may reduce the risk of postoperative urinary retention after hernia and colorectal surgery, but evidence is lacking.
View Article and Find Full Text PDFEarly experience of prostate artery embolization: a retrospective single-centre study.
Scand J Urol
January 2025
Center for Clinical Research Västmanland, Uppsala University, Sweden; Division of Surgery, Danderyd University Hospital, Stockholm, Sweden.
Objective: The aim of this study was to evaluate the early experiences of prostate artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).
Material And Methods: This retrospective study included all patients treated for BPH who were referred to the radiology department for PAE in Västmanland between 2018 and 2021. Data were collected on patient demographics, International Prostate Symptom Score (IPSS), prostate-specific antigen level, and peri- and post-procedure outcomes.
Rationale and design of the beta-blockers in tako-tsubo syndrome study: a randomized clinical trial (β-Tako).
Rev Esp Cardiol (Engl Ed)
December 2024
Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Catholic University of the Sacred Heart, Rome, Italy.
Unlabelled: Introduction y objectives: Tako-tsubo syndrome (TTS) is a cardiac condition that mimics acute coronary syndrome, characterized by transient left ventricular dysfunction in the absence of culprit coronary artery stenosis. Although its etiology remains unknown, reversible microvascular dysfunction secondary to an adrenergic surge is thought to play a role. Treatment is empirical, although most patients receive beta-blockers (BB) in clinical practice.
View Article and Find Full Text PDFTamsulosin ameliorates bone loss by inhibiting the release of Cl through wedging into an allosteric site of TMEM16A.
Proc Natl Acad Sci U S A
January 2025
National Key Laboratory of Space Medicine, China Astronaut Research and Training Center, Beijing 100094, China.
TMEM16A, a key calcium-activated chloride channel, is crucial for many physiological and pathological processes such as cancer, hypertension, and osteoporosis, etc. However, the regulatory mechanism of TMEM16A is poorly understood, limiting the discovery of effective modulators. Here, we unveil an allosteric gating mechanism by presenting a high-resolution cryo-EM structure of TMEM16A in complex with a channel inhibitor that we identified, Tamsulosin, which is resolved at 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!